ACPU
ABBV icon

Arrowgrass Capital Partners (US)’s AbbVie ABBV Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$5.84M Sell
65,970
-88,100
-57% -$7.31M 1.54% 24
2019
Q3 		$11.7M Buy
154,070
+46,918
+44% +$3.22M 0.87% 30
2019
Q2 		$7.79M Buy
107,152
+32,501
+44% +$2.55M 0.18% 145
2019
Q1 		$6.02M Buy
74,651
+44,220
+145% +$3.62M 0.18% 165
2018
Q4 		$2.81M Buy
+30,431
New +$2.68M 0.1% 181
2017
Q2 		– Sell
-28,946
Closed -$1.95M – 599
2017
Q1 		$1.89M Sell
28,946
-38,853
-57% -$2.44M 0.02% 430
2016
Q4 		$4.25M Buy
67,799
+10,596
+19% +$647K 0.05% 278
2016
Q3 		$3.61M Buy
57,203
+35,458
+163% +$2.3M 0.05% 247
2016
Q2 		$1.35M Sell
21,745
-132,909
-86% -$8.1M 0.01% 311
2016
Q1 		$8.83M Buy
154,654
+93,655
+154% +$5.22M 0.11% 133
2015
Q4 		$3.61M Sell
60,999
-39,001
-39% -$2.25M 0.04% 189
2015
Q3 		$5.44M Buy
100,000
+50,000
+100% +$3.25M 0.1% 153
2015
Q2 		$3.36M Sell
50,000
-111,716
-69% -$7.29M 0.05% 257
2015
Q1 		$9.47M Buy
+161,716
New +$9.77M 0.15% 87

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s ABBV Position: Q4 2019 in Review

Arrowgrass Capital Partners (US) reduced its AbbVie (ABBV) stake by 57% in Q4 2019, selling an estimated $7.31M and leaving 65,970 shares worth $5.84M. The position accounts for 1.54% of the portfolio, ranked #24.

Arrowgrass Capital Partners (US) first reported a position in ABBV in Q1 2015 and has held it in 14 quarters since. The position peaked at $11.7M in Q3 2019. 2,244 funds tracked by Wall St. Rank hold ABBV as of Q4 2019.

  • Arrowgrass Capital Partners (US) held 65,970 shares of AbbVie worth $5.84M as of Q4 2019.
  • Arrowgrass Capital Partners (US) sold 88,100 AbbVie shares in Q4 2019, an estimated $7.31M.
  • AbbVie made up 1.54% of Arrowgrass Capital Partners (US)'s portfolio in Q4 2019, its #24 holding.
  • Arrowgrass Capital Partners (US) first reported a position in AbbVie in Q1 2015 and has held it in 14 quarters since.
  • Arrowgrass Capital Partners (US)'s AbbVie position peaked at $11.7M in Q3 2019.
  • 2,244 funds tracked by Wall St. Rank held AbbVie as of Q4 2019.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q4 2019, filed 14 Feb 2020.